Reports indicate that transcription factor PPARγ inhibits the expression of several MMPs by antagonizing the activities of AP-1 and NFκB and has recently been considered as an important target for development of new drugs for cancer therapy [26]–[28], [47]. Here, PPARG is linked to cancer.